For women, increased risk for breast cancer merits similar management to BRCA1 or BRACA2 carriers: clinical breast examination starting at 25 years of age or 5–10 years before the earliest known breast cancer in the family (whichever comes first). The gene discussed is BRCA1; the disease is breast cancer.